<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503943</url>
  </required_header>
  <id_info>
    <org_study_id>BLOOD</org_study_id>
    <nct_id>NCT02503943</nct_id>
  </id_info>
  <brief_title>Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes</brief_title>
  <official_title>What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone（BLOOD STUDY）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital of Third Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital of Third Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is one of the characteristics of type 2 diabetes mellitus. Most of the obese diabetes
      patients are combined with dyslipidemia or hypertension. The clustering of diabetes, obesity,
      hypertension and dyslipidemia increases the risk of cardiovascular events for patients. GLP-1
      (glucagon like peptide-1) is a kind of incretin discovered in recent years. It was reported
      that beside its hypoglycemic and losing weight effects, activator of GLP-1 receptor could
      decrease blood pressure and improve lipid metabolism. Therefore, activation of GLP-1 receptor
      may become a new comprehensive treatment strategies for improving glucose and lipid
      metabolism, blood pressure level and cardiovascular complication. But, it is lack of
      evidence-based medicine proof on the relationship between GLP-1 and blood pressure or serum
      lipid. So, investigators designed a prospective, randomized, open-label, active control
      study, and try to evaluate the effects of activator of GLP-1 receptor (liraglutide) on
      lowering blood pressure, improving vascular function and lipid metabolism in overweight or
      obese type 2 diabetic patients with masked hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure change</measure>
    <time_frame>Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid profile (triglyceride, total cholesterol, LDL-c; HDL-c; mmol/L) change</measure>
    <time_frame>Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hours mean blood pressure; incidence of clinical hypertension; Blood pressure variability, Heart rate variability.</measure>
    <time_frame>Baseline，12 weeks,up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics parameters, including pulse wave velocity(PWV)</measure>
    <time_frame>Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hours urine sodium and microalbumin</measure>
    <time_frame>Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid intima-media thickness(IMT,mm)</measure>
    <time_frame>Baseline，12 weeks,up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obesity parameters, including waist circumference (WC,cm) and body mass index(BMI, kg/m2)</measure>
    <time_frame>Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance assessed by fasting serum insulin and HOMA-IR, and control rate of diabetes.</measure>
    <time_frame>Baseline,4 weeks,8 weeks,12 weeks,16 weeks,20 weeks,up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <condition>Masked Hypertension</condition>
  <arm_group>
    <arm_group_label>&quot;Liraglutide&quot; and &quot;Mitiglinide&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&quot;Liraglutide&quot;(1.2mg/d) and &quot;Mitiglinide&quot;(50mg, 3/d)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Metformin&quot; and &quot;Mitiglinide&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;Metformin&quot;(500mg, 3/d) and &quot;Mitiglinide&quot;(50mg, 3/d)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;Mitiglinide&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;Mitiglinide&quot;(50mg, 3/d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>&quot;Liraglutide&quot; and &quot;Mitiglinide&quot;</intervention_name>
    <description>&quot;Liraglutide&quot;(1.2mg/d) and &quot;Mitiglinide&quot; (50mg, 3/d)</description>
    <arm_group_label>&quot;Liraglutide&quot; and &quot;Mitiglinide&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>&quot;Metformin&quot; and &quot;Mitiglinide&quot;</intervention_name>
    <description>&quot;Metformin&quot;(500mg, 3/d) and &quot;Mitiglinide&quot;(50mg, 3/d)</description>
    <arm_group_label>&quot;Metformin&quot; and &quot;Mitiglinide&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>&quot;Mitiglinide&quot;</intervention_name>
    <description>&quot;Mitiglinide&quot; (50mg, 3/d)</description>
    <arm_group_label>&quot;Mitiglinide&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, age between 35-60 years old

          2. Type 2 diabetes

          3. 24kg/m²≤BMI≤32kg/m², or WC≥90cm for male and WC≥85cm for female

          4. Grade 1 hypertension or masked hypertension diagnosed via 24-h ambulatory blood
             pressure monitoring (daytime blood pressure load 50%≥135/85 mmHg, night time blood
             pressure load 50%≥125/75 mmHg or 24h blood pressure load 50%≥130/80 mmHg）

        Exclusion Criteria:

          1. Type 2 diabetes with serious complications, such as diabetic neuropathy, diabetic
             retinopathy, stage IV diabetic nephropathy, or acute diabetic complications.

          2. Type 1 diabetes.

          3. Diagnosed moderate to severe sleep apnea syndrome(SAS).

          4. Grade 2 or Grade 3 hypertension.

          5. Triglyceride≥5.65mmol/L

          6. History of cardio-cerebral vascular events such as congestive heart failure,
             myocardial infarction or stroke within 3 months.

          7. Hypohepatia (AST or AST is twice higher than the upper limit) or history of hepatitis
             or cirrhosis, hepatic encephalopathy.

          8. Renal insufficiency ( serum creatinine is 1.5 times higher than the upper limit) or
             history of dialysis and nephritic syndrome.

          9. Chronic obstructive pulmonary disease (COPD), chronic respiratory failure or hyoxemia.

         10. Acute infections, tumor, severe arrhythmia, mental disorders, alcohol or medicine
             addiction.

         11. Fertile woman without contraceptives.

         12. Any surgical or medical conditions that significantly influence absorption,
             distribution, metabolism or excretion of the intervention drugs.

         13. Allergic to or have contraindication to the intervention drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiming Zhu, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>The third hospital affiliated to the Third Military Medical University. China</affiliation>
  </overall_official>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <last_update_submitted>July 19, 2015</last_update_submitted>
  <last_update_submitted_qc>July 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital of Third Military Medical University</investigator_affiliation>
    <investigator_full_name>Yinxing Ni</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>GLP-1</keyword>
  <keyword>Masked hypertension</keyword>
  <keyword>Lipid metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Masked Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitiglinide</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

